Organigram (OGI) Competitors $1.51 -0.01 (-0.66%) (As of 12/12/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends OGI vs. ABUS, ALT, ORIC, OCS, TRML, RNAC, DNA, PHAT, EXAI, and IGMSShould you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Arbutus Biopharma (ABUS), Altimmune (ALT), ORIC Pharmaceuticals (ORIC), Oculis (OCS), Tourmaline Bio (TRML), Cartesian Therapeutics (RNAC), Ginkgo Bioworks (DNA), Phathom Pharmaceuticals (PHAT), Exscientia (EXAI), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical products" industry. Organigram vs. Arbutus Biopharma Altimmune ORIC Pharmaceuticals Oculis Tourmaline Bio Cartesian Therapeutics Ginkgo Bioworks Phathom Pharmaceuticals Exscientia IGM Biosciences Organigram (NASDAQ:OGI) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends. Does the media favor OGI or ABUS? In the previous week, Organigram had 11 more articles in the media than Arbutus Biopharma. MarketBeat recorded 13 mentions for Organigram and 2 mentions for Arbutus Biopharma. Organigram's average media sentiment score of 0.77 beat Arbutus Biopharma's score of 0.62 indicating that Organigram is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organigram 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in OGI or ABUS? 34.6% of Organigram shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 0.1% of Organigram shares are held by insiders. Comparatively, 4.0% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is OGI or ABUS more profitable? Organigram has a net margin of -45.57% compared to Arbutus Biopharma's net margin of -1,137.65%. Organigram's return on equity of -16.76% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Organigram-45.57% -16.76% -14.32% Arbutus Biopharma -1,137.65%-68.18%-51.55% Do analysts recommend OGI or ABUS? Arbutus Biopharma has a consensus price target of $5.50, suggesting a potential upside of 54.49%. Given Arbutus Biopharma's higher probable upside, analysts plainly believe Arbutus Biopharma is more favorable than Organigram.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor OGI or ABUS? Arbutus Biopharma received 236 more outperform votes than Organigram when rated by MarketBeat users. Likewise, 71.03% of users gave Arbutus Biopharma an outperform vote while only 70.71% of users gave Organigram an outperform vote. CompanyUnderperformOutperformOrganigramOutperform Votes19870.71% Underperform Votes8229.29% Arbutus BiopharmaOutperform Votes43471.03% Underperform Votes17728.97% Which has more volatility and risk, OGI or ABUS? Organigram has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Which has higher valuation & earnings, OGI or ABUS? Arbutus Biopharma has lower revenue, but higher earnings than Organigram. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganigram$161.08M1.02-$184.34M-$0.42-3.60Arbutus Biopharma$18.14M37.19-$72.85M-$0.43-8.28 SummaryArbutus Biopharma beats Organigram on 9 of the 17 factors compared between the two stocks. Ad The Oxford ClubThis could bring inflation roaring back (I’m concerned)"For AI... We have to produce massive electricity that we don't have. Nuclear has become very safe, very good." - President TrumpHere's why nuclear stocks are expected to skyrocket under Trump's second term. Get Organigram News Delivered to You Automatically Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGI vs. The Competition Export to ExcelMetricOrganigramPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$164.46M$6.83B$5.13B$9.23BDividend YieldN/A2.87%5.16%3.99%P/E Ratio-3.6011.06107.1317.76Price / Sales1.02217.751,299.62127.82Price / CashN/A22.7036.1835.66Price / Book0.615.274.884.89Net Income-$184.34M$152.46M$116.33M$225.53M7 Day Performance4.14%-1.69%-0.22%0.23%1 Month Performance-5.03%-7.35%-2.11%3.64%1 Year Performance19.84%20.64%32.09%27.19% Organigram Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGIOrganigram1.1109 of 5 stars$1.51-0.7%N/A+15.2%$164.46M$161.08M-3.60860Upcoming EarningsAnalyst RevisionNews CoverageABUSArbutus Biopharma2.1841 of 5 stars$3.70+0.5%$5.50+48.6%+77.6%$701.11M$18.14M0.0073ALTAltimmune2.1008 of 5 stars$9.68+6.3%$20.00+106.6%+68.1%$688.44M$430,000.000.0050ORICORIC Pharmaceuticals3.9241 of 5 stars$9.62-2.8%$18.29+90.1%+0.3%$678.88MN/A0.0080Positive NewsOCSOculis2.4412 of 5 stars$16.48+0.3%$29.20+77.2%+37.7%$667.44M$980,000.000.002Gap UpTRMLTourmaline Bio2.3195 of 5 stars$25.50-1.7%$61.25+140.2%+31.9%$653.82MN/A0.0044Analyst ForecastNews CoverageRNACCartesian Therapeutics2.2913 of 5 stars$25.59+1.8%$43.00+68.0%+18.4%$650.50M$26M0.0037DNAGinkgo Bioworks0.8655 of 5 stars$11.17-4.2%$4.58-59.0%N/A$642.05M$251.46M0.001,218PHATPhathom Pharmaceuticals2.7539 of 5 stars$9.35+3.9%$22.50+140.6%+3.6%$639.33M$26.27M-1.63110Analyst ForecastNews CoveragePositive NewsEXAIExscientia1.7174 of 5 stars$4.84flat$7.00+44.6%N/A$632.93M$25.60M-3.21280IGMSIGM Biosciences4.5887 of 5 stars$10.57+2.5%$16.67+57.7%+49.2%$628.49M$2.13M0.00190 Related Companies and Tools Related Companies ABUS Competitors ALT Competitors ORIC Competitors OCS Competitors TRML Competitors RNAC Competitors DNA Competitors PHAT Competitors EXAI Competitors IGMS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OGI) was last updated on 12/12/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThis could bring inflation roaring back (I’m concerned)"For AI... We have to produce massive electricity that we don't have. Nuclear has become very safe, very good....The Oxford Club | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCaught on camera (shocking new AI tech)Everyone is talking about the “Magnificent Seven"... Nvidia, Meta, Google, Microsoft, etc. Meanwhile, they ...Banyan Hill Publishing | SponsoredThis happened before the 1987 crash too…I’d urge you to watch my latest exposé into what’s really going on in the tech sector… why I believe we could ...Porter & Company | SponsoredPrepare Now Before This Looming $2 Trillion D.C. ShockMillions of traders could get blindsided by this election-year shock on December 18th… And if you do nothin...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organigram Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organigram With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OGI Stock Alerts